Cytosorbents Corp (CTSO)
NASDAQ:CTSO
Earnings Data
Report Date
May 05, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.04Last Year’s EPS
-0.02Same Quarter Last Year
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presents a balanced picture: meaningful operational and clinical progress (double‑digit international growth, high gross margins, clinical publication, PuriFi placements) and a clear path to reduce costs and target cash flow breakeven in H2 2026. Offsetting factors include a near‑term revenue hit in Germany from restructuring, persistent adjusted losses, a modest cash balance with recent operating cash burn and an unresolved FDA resubmission timeline for DrugSorb‑ATR. Highlights demonstrate strategic traction and clinical validation, but financial and regulatory risks create near‑term uncertainty.Company Guidance
Full Year Revenue Growth
Full year 2025 revenue increased 4% to $37.1 million (flat on a constant currency basis), representing record core product sales.
International Expansion Driving Growth
Direct sales outside Germany grew 13% to $8.6 million and distributor sales grew 11.4% to $16.5 million; together these channels accounted for ~68% of total revenue, highlighting increasing diversification.
Strong Gross Margins
Gross margin was 71% for the full year 2025 and improved to 74% in Q4 2025, driven by manufacturing efficiencies.
Progress Toward Cash Flow Breakeven
Operating loss improved 10% to $14.7 million for 2025 and adjusted EBITDA loss improved 9% to $10.5 million; company expects operating cash flow breakeven in the second half of 2026 after cost reductions and working capital normalization.
Clinical and Regulatory Momentum for DrugSorb-ATR
STAR-T randomized controlled trial published in JTCVS showing DrugSorb-ATR was safe and reduces severity of bleeding in high‑risk CABG patients; ongoing interactive discussions with FDA after an appeal confirmed no device safety concerns and narrowed remaining items for resubmission.
Product and Adoption Initiatives
PuriFi pump placements exceeded 100 units globally to expand access and enable earlier intervention; HotSwap exchange innovation launched with positive clinician feedback at ISICEM; >300,000 CytoSorb treatments delivered across 70 countries.
Reduced R&D and Improved Expense Discipline
Full year operating expenses were relatively flat at $41.2 million and included $2.5 million lower R&D spend (lower clinical and project spend) alongside targeted SG&A increases for regulatory/commercial initiatives; workforce restructuring aimed to lower ongoing cash burn.
CTSO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CTSO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 25, 2026 | $0.67 | $0.60 | -10.58% |
Nov 13, 2025 | $0.67 | $0.66 | -0.75% |
Aug 07, 2025 | $0.89 | $1.00 | +11.98% |
May 14, 2025 | $0.81 | $0.83 | +3.22% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Cytosorbents Corp (CTSO) report earnings?
Cytosorbents Corp (CTSO) is schdueled to report earning on May 05, 2026, After Close (Confirmed).
What is Cytosorbents Corp (CTSO) earnings time?
Cytosorbents Corp (CTSO) earnings time is at May 05, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CTSO EPS forecast?
CTSO EPS forecast for the fiscal quarter 2026 (Q1) is -0.04.